

# FIFTH MEETING OF THE VECTOR CONTROL ADVISORY GROUP

VCAAG



GENEVA, SWITZERLAND  
2-4 NOVEMBER 2016



**World Health  
Organization**

The support provided by the Bill and Melinda Gates Foundation (Grant No OPP1032376) for the work of Vector Control Advisory Group is gratefully acknowledged.

This report was produced by the Vector Ecology and Management Unit, Department of Control of Neglected Tropical Diseases, and the Vector Control Unit of the Global Malaria Programme of the World Health Organization.

Design & Layout: Patrick Tissot WHO/HTM/NTD

# FIFTH MEETING OF THE VECTOR CONTROL ADVISORY GROUP



GENEVA, SWITZERLAND  
2–4 NOVEMBER 2016



**World Health  
Organization**

.....  
.....  
.....  
.....  
.....  
.....

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence [CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>].

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Fifth meeting of the vector control advisory group, Geneva, Switzerland, 2–4 November 2016. Geneva: World Health Organization; 2017 (WHO/HTM/NTD/VEM/2017.02). Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in France.

WHO/HTM/NTD/VEM/2017.02

# CONTENTS

Abbreviations and glossary	v
Declarations of interest	vi
1. SUMMARY	1
2. BACKGROUND AND OPENING REMARKS	2
2.1 Update on WHO draft Global Vector Control Response	3
2.2 Briefing on multi-country study on insecticide resistance	4
2.3 Overview of terms of reference of the Group	4
3. WHO PATHWAYS FOR NEW TOOLS	8
4. COMBINED STERILE INSECT TECHNIQUE AND INCOMPATIBLE INSECT TECHNIQUE FOR MOSQUITO POPULATION CONTROL	13
4.1 Overview of the intervention concept	13
4.1.1 Background summary	13
4.1.2 Description of the intervention concept	14
4.1.3 Description of the prototype product	17
4.1.4 Product claims	17
4.1.5 Justification for the claims	17
4.1.6 Evidence reviewed from key studies in support of claims	18
4.1.7 List of publications cited in the submission	19
4.2 Conclusions and recommendations of the Group	21
5. REDUCING VECTOR POPULATIONS THROUGH GENETIC MANIPULATION	23
5.1 Overview of the intervention concept	23
5.1.1 Background summary	23
5.1.2 Description of the intervention concept	23
5.1.3 Description of the prototype product	25
5.1.4 Product claims	25
5.1.5 Justification for the claims	25
5.1.6 Evidence reviewed from key studies in support of claims	26
5.1.7 List of publications cited in the submission	28
5.2 Conclusions and recommendations of the Group	28
6. ALTERING VECTOR POPULATIONS THROUGH GENETIC MANIPULATION	31
6.1 Overview of the intervention concept	31
6.1.1 Background summary	31
6.1.2 Description of the intervention concept	32
6.1.3 Description of the prototype product	32

6.1.4 Product claims	33
6.1.5 Justification for the claims	33
6.1.6 Evidence reviewed from key studies in support of claims	35
6.1.7 List of publications cited in the submission	36
6.2 Conclusions and recommendations of the Group	38

## 7. STATUS UPDATES ON PREVIOUS SUBMISSIONS-----40

7.1 Spatial repellents	40
7.2 Oxitec OX513A	40
7.3 Interceptor G2	41
7.4 Eave tubes	41

## ANNEXES -----42

Annex 1. Agenda	42
Annex 2. List of participants	43
Annex 3. Terms of reference of the Vector Control Advisory Group	45
Annex 4. Overview of existing and new product classes and claims	49
Annex 5. Evaluation pathways for vector control tools interventions (tools, technologies and approaches)	53

## ABBREVIATIONS AND GLOSSARY

Effectiveness	Estimates the effect of an intervention under programmatic or real-life conditions (e.g. delivery of the intervention under routine conditions to maximize the relevance of the findings for policy and practice)
Efficacy	Estimates the effect of an intervention under highly controlled conditions (e.g. maximal coverage of the target population and adherence to the intervention)
IAEA	International Atomic Energy Agency
FAO	Food and Agriculture Organization of the United Nations
GMP	Global Malaria Programme
IIT	incompatible insect technique
IRS	indoor residual spraying
LLIN	long-lasting insecticidal net
NTD	neglected tropical disease
PQ	Prequalification Programme
Product class	For vector control, a category of intervention that shares a common entomological mechanism of action to reduce infection and/or disease
SIT	sterile insect technique
TDR	Special Programme for Research and Training in Tropical Diseases
TPP	target product profile
VCAG	Vector Control Advisory Group
VEM	Vector Ecology and Management unit
WHO	World Health Organization
WHOPES	WHO Pesticide Evaluation Scheme

## DECLARATIONS OF INTEREST

All invited experts completed a declaration of interests form for WHO experts before the meeting, which was submitted to and assessed by the WHO Secretariat. On review of the completed forms, the following expert declared interests that required further consideration and discussion with the Office of Compliance, Risk Management and Ethics:

- Professor Immo Kleinschmidt

Further to a meeting with the Office of Compliance, Risk Management and Ethics, the technical units sought additional information from the expert regarding their respective disclosed interests:

Professor Immo Kleinschmidt is a Professor of Epidemiology at the London School of Hygiene & Tropical Medicine. In his declaration, he noted that his Research Unit receives institutional research funding from the Bill & Melinda Gates Foundation via Penn State University to assist in the development of the Eaves Tubes Trial methodology. This information was shared with the Office of Compliance, Risk Management and Ethics.

### Conclusion

Upon receipt and review of the additional information, it was determined that this interest was potentially significant as it relates directly to the subject of activity for one session of this meeting (eave tubes). Due to this interest, Professor Kleinschmidt did not participate in the drafting and finalization of the recommendations on eave tubes: partial exclusion.

The reported interest was publicly disclosed to other meeting participants and recorded during the meeting. Participants were notified that interests will be disclosed in the report of the meeting and relevant publications or work products.

**预览已结束，完整报告链接和**

<https://www.yunbaogao.cn/report/index/report>